Literature DB >> 1993949

Dose dependency of time of onset of radiation-induced growth hormone deficiency.

P E Clayton1, S M Shalet.   

Abstract

Growth hormone (GH) secretion during insulin-induced hypoglycemia was assessed on 133 occasions in 82 survivors of childhood malignant disease. All had received cranial irradiation with a dose range to the hypothalamic-pituitary axis of 27 to 47.5 Gy (estimated by a schedule of 16 fractions over 3 weeks) and had been tested on one or more occasions between 0.2 and 18.9 years after treatment. Results of one third of the GH tests were defined as normal (GH peak response, greater than 15 mU/L) within the first 5 years, in comparison with 16% after 5 years. Stepwise multiple linear regression analysis showed that dose (p = 0.007) and time from irradiation (p = 0.03), but not age at therapy, had a significant influence on peak GH responses. The late incidence of GH deficiency was similar over the whole dose range (4 of 26 GH test results normal for less than 30 Gy and 4 of 25 normal for greater than or equal to 30 Gy after 5 years), but the speed of onset over the first years was dependent on dose. We conclude that the requirement for GH replacement therapy and the timing of its introduction will be influenced by the dose of irradiation received by the hypothalamic-pituitary axis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1993949     DOI: 10.1016/s0022-3476(05)80487-1

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  18 in total

Review 1.  Endocrine dysfunctions in patients treated for brain tumors: incidence and guidelines for management.

Authors:  A A Brandes; L M Pasetto; F Lumachi; S Monfardini
Journal:  J Neurooncol       Date:  2000-03       Impact factor: 4.130

Review 2.  Pediatric brain tumor treatment: growth consequences and their management.

Authors:  Sogol Mostoufi-Moab; Adda Grimberg
Journal:  Pediatr Endocrinol Rev       Date:  2010-09

3.  Pituitary hormone dysfunction after proton beam radiation therapy in children with brain tumors.

Authors:  Vidhya Viswanathan; Kamnesh R Pradhan; Erica A Eugster
Journal:  Endocr Pract       Date:  2011 Nov-Dec       Impact factor: 3.443

Review 4.  Hypopituitarism as a consequence of brain tumours and radiotherapy.

Authors:  Ken H Darzy; Stephen M Shalet
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

5.  An intensive multiagent chemotherapy regimen for brain tumours occurring in very young children.

Authors:  L S Lashford; R H Campbell; H R Gattamaneni; K Robinson; D Walker; C Bailey
Journal:  Arch Dis Child       Date:  1996-03       Impact factor: 3.791

6.  Sexually dimorphic and radiation dose dependent effect of cranial irradiation on body mass index.

Authors:  F Craig; A D Leiper; R Stanhope; C Brain; S T Meller; S S Nussey
Journal:  Arch Dis Child       Date:  1999-12       Impact factor: 3.791

7.  Inhibition of the MET Receptor Tyrosine Kinase as a Novel Therapeutic Strategy in Medulloblastoma.

Authors:  Paul N Kongkham; Sara Onvani; Christian A Smith; James T Rutka
Journal:  Transl Oncol       Date:  2010-12-01       Impact factor: 4.243

8.  Endocrine Deficiency As a Function of Radiation Dose to the Hypothalamus and Pituitary in Pediatric and Young Adult Patients With Brain Tumors.

Authors:  Ralph E Vatner; Andrzej Niemierko; Madhusmita Misra; Elizabeth A Weyman; Claire P Goebel; David H Ebb; Robin M Jones; Mary S Huang; Anita Mahajan; David R Grosshans; Arnold C Paulino; Takara Stanley; Shannon M MacDonald; Nancy J Tarbell; Torunn I Yock
Journal:  J Clin Oncol       Date:  2018-08-17       Impact factor: 44.544

Review 9.  Hypopituitarism following radiotherapy.

Authors:  Ken H Darzy; Stephen M Shalet
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

10.  Longitudinal growth and final height in long-term survivors of childhood leukaemia.

Authors:  A Cicognani; E Cacciari; P Rosito; A F Mancini; G Carlă; M Mandini; G Paolucci
Journal:  Eur J Pediatr       Date:  1994-10       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.